<DOC>
	<DOC>NCT01961505</DOC>
	<brief_summary>Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability. It has been confirmed that tripterygium extract has effects of anti-inflammatory, immunosuppressive and cartilage protection. This is a prospective randomized controlled study to evaluated the efficacy and safety of external application with compound tripterygium gel in treating of patients with rheumatoid arthritis (RA).</brief_summary>
	<brief_title>External Therapy With Compound Tripterygium Gel for Decreasing Disease Activity in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Documented diagnosis of rheumatoid arthritis, as defined by the American Rheumatism Association 1987 Revised Criteria or European League Against Rheumatism criteria (2009). Patients must have moderately to severely active RA,and the DAS28 score should be from 3.2 to 5.1. If taking disease modifying antirheumatic drug (DMARDs)(e.g.Methotrexate), subject must have been on a stable dose for ≥ 3 months prior to randomization. If taking nonsteroidal antiinflammatory drugs (NSAIDs), subject must have been on a stable dose for ≥ 4 weeks prior to randomization. 16 to 65 years old, having signed the informed consent. Patients who have skin burst or allergies. Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and hematopoietic system. Patients who have been treated by tripterygium, hormones or biological agents. Patients who have not been treated by DMARDs before. Patients who are unwilling to comply with all study procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>